Claims for Patent: 4,703,108

Summary for Patent: 4,703,108

Title:	Biodegradable matrix and methods for producing same
Abstract:	There are disclosed processes for preparing biodegradable collagen-based matrices in sponge or sheet form wherein in one embodiment a collagen-based material including a collagen selected from the group consisting of types I, II and II collagens is freeze dried to form a collagen-based sponge which is contacted with a cross-linking agent selected from the group consisting of a carbodiimide or a succinimidyl active ester to form an intermediate collagen-based matrix which is subsequently subjected to conditions of severe dehydration to form the collagen-based matrix in sponge or sheet form. In another embodiment, a collagen-based sponge or sheet is first subjected to conditions of severe dehydration followed by contacting the thus formed intermediate collagen-based matrix with a carbodiimide crosslinking compound to form the collagen-based matrix in sponge or sheet form. In still another embodiment of the present invention the cross-linking agent is admixed with the collagen-based material prior to formation of the collagen-based sponge or sheet followed by processing steps of severe dehydration. In a particularly preferred form of the invention, a carrier compound is incorporated during processing to form a collagen-based matrix in sponge or sheet form impregnated with a carrier compound wherein the carrier compound is selected from the group consisting of types IV and V collagen, fibronectin, laminin, hyaluronate, proteoglycan, epidermal growth factor, platelet derived growth factor, angiogenesis factor, antibiotic, antifungal agent, spermacidal agent, enzyme and enzyme inhibitor.
Inventor(s):	Silver; Frederick A. (Long Valley, NJ), Berg; Richard A. (Lambertville, NJ), Birk; David E. (Somerset, NJ), Weadock; Kevin (Piscataway, NJ), Whyne; Conrad (Somerset, NJ)
Assignee:	University of Medicine & Dentistry of New Jersey (Newark, NJ)
Application Number:	06/843,828
Patent Claims:	1. The process for the preparation of a cross-linked collagen matrix which comprises two cross-linking steps of: (a) contacting collagen with a cross-linking agent selected from the group consisting of a carbodiimide and a combination of a bifunctional succinimidyl active ester and a carbodiimide, and (b) subjecting collagen to elevated temperatures under vacuum. 2. The process of claim 1 wherein step (a) is performed prior to step (b). 3. The process of claim 1 wherein step (b) is performed prior to step (a). 4. The process of claim 1 wherein the cross-linking agent in step (a) is a carbodiimide. 5. The process of claim 4 wherein the carbodiimide is selected from the group consisting of cyanamide and 1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide hydrochloride. 6. The process of claim 1 wherein the cross-linking agent is a combination of carbodiimide and a bifunctional succinimidyl active ester. 7. The process of claim 6 wherein the bifunctional succinimidiyl active ester is selected from the group consisting of bifunctional N-hydroxy succinimide, 3,3-dithro(sulfo-succinimidyl)propionate and bis(sulfosuccinimidyl) suberate and the carbodiimide is selected from the group consisting of cyanamide and 1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide hydrochloride. 8. The process of claim 1 wherein step (b) is carried out at a temperature of from 50.degree. C. to 200.degree. C. at a vacuum of 50 millitorr or less. 9. The process of claim 8 wherein the temperature is 100.degree. C. 10. A cross-linked matrix made according to the process of claim 1. 11. A carbodiimide and dehydrothermal cross-linked biodegradable collagen matrix which promotes fibroblast ingrowth when implanted subcutaneously or placed directly on a full thickness dermal wound. 12. The cross-linked matrix of claim 11 wherein the collagen has a minimum molecular weight of at least 1.0.times.10.sup.6 daltons. 13. The cross-linked matrix of claim 12 wherein the minimum molecular weight is in excess of 50.times.10.sup.6 daltons. 14. The cross-linked matrix of claim 11 wherein the molecular weight of the matrix between the covalent bond cross-links is from a minimum of 1,000 daltons to a maximum of 100,000 daltons. 15. The cross-linked matrix of claim 11 in sheet form. 16. The cross-linked matrix of claim 11 having a swelling ratio of at least about 2.5. 17. The cross-linked matrix of claim 11 which further includes a diffusion layer. 18. The cross-linked matrix of claim 17 wherein the matrix combined with the diffusion layer has a tensile strength of at least 100 psi. 19. The cross-linked matrix of claim 11 which further includes a compound selected from the group consisting of hyaluronate, fibronectin, laminin, proteoglycan, epidermal growth factor, platelet derived growth factor, angiogenesis factor, antibiotic, antifungal agent, spermicidal agent, enzyme and enzyme inhibitor, wherein the compound is cross-linked within the matrix. 20. The cross-linked matrix of claim 19 in sheet form. 21. The cross-linked matrix of claim 19 having a swelling ratio of at least about 2.5. 22. The cross-linked matrix of claim 19 which further includes a diffusion layer. 23. A carbodiimide and dehydrothermal cross-linked biodegradable matrix which consists essentially of collagen and promotes fibroblast ingrowth when implanted subcutaneously or placed directly on a full thickness dermal wound. 24. The cross-linked matrix of claim 23 wherein the collagen has a minimum molecular weight of at least 1.0.times.10.sup.6 daltons. 25. The cross-linked matrix of claim 23 wherein the minimum molecular weight is in excess of 50.times.10.sup.6 daltons. 26. The cross-linked matrix of claim 23 wherein the molecular weight of the matrix between the covalent bond cross-links is from a minimum of 1,000 to a maximum of 100,000 daltons. 27. The cross-linked matrix of claim 23 in sheet form. 28. The cross-linked matrix of claim 23 having a swelling ratio of at least about 2.5. 29. The cross-linked matrix of claim 23 which further includes a diffusion layer. 30. The cross-linked matrix of claim 23 wherein the matrix combined with the diffusion layer has a tensile strength of at least 100 psi. 31. A carbodiimide and dehydrothermal cross-linked collagen matrix which consists essentially of collagen and a compound selected from the group consisting of hyaluronate fibronectin, laminin, proteglycan, epidermal growth factor, platelet derived growth factor, angiogenesis factor, antibiotic, antifungal agent, spermicidal agent, enzyme and enzyme inhibitor, wherein the compound is cross-linked within the matrix, which matrix promotes fibroblast ingrowth when implanted subcutaneously or placed directly on a full thickness dermal wound. 32. The cross-linked matrix of claim 32 in sheet form. 33. The cross-linked matrix of claim 32 having a swelling ratio of at least about 2.5. 34. The cross-linked matrix of claim 32 which further includes a diffusion layer. 35. The cross-linked matrix of claim 11 wherein the collagen is selected from the group consisting of Type I, Type II and Type III collagen. 36. The cross-linked matrix of claim 11 which has a collagenase resistance time to clostridium histoylicum of from about 720 to about 3180 minutes per cm.sup.2 of matrix. 37. The cross-linked matrix of claim 32 which further has a high strain modulus of from about 1186 to about 3434 g/mm. 38. The process of claim 1 wherein prior to the two crossing steps, the collagen is dispersed in dilute hydrochloric acid.

Details for Patent 4,703,108

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Smith & Nephew, Inc.	SANTYL	collagenase	Ointment	101995	06/04/1965		2004-10-27